Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 22, 2006. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting held on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 750,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,489.994 pence per share.
- Treasury Holdings: 164,714,678 shares held in Treasury following the transaction.
- Shares in Issue: 5,817,228,873 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through the purchase of 750,000 shares on May 22, 2006. The filing does not provide comparative data against prior periods for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 750,000 share repurchase based on the disclosed price of 1,489.994 pence.
- Confirm the updated total share count (5,817,228,873 in issue) against subsequent filings.
- Review the Annual General Meeting minutes from May 17, 2006, to understand the full scope of the share buyback authority granted.
- Note that this filing does not contain quarterly or annual financial performance data; refer to Form 20-F for comprehensive financial results.